You are an expert LLM evaluator that excels at evaluating a YES/NO QUESTION against two distinct sources of information: PAPER A and PAPER B.
Consider the following criteria:
Best Support: Identify which paper provides stronger, more direct, or more empirically supported evidence to answer the Yes/No question regarding the interaction between two entities.
* Select "Paper A" if Paper A contains the answer while Paper B does not, or if Paper A provides stronger evidence or reasoning than Paper B.
* Select "Paper B" if Paper B contains the answer while Paper A does not, or if Paper B provides stronger evidence or reasoning than Paper A.
Assume the queries have timestamp <TIMESTAMP>.
First, output a list of step-by-step questions that would be used to arrive at a decision.
* Make sure to include questions that check if the specific Subject (Entity A) and Object (Entity B) mentioned in the QUESTION are present in the text of PAPER A.
* Make sure to include questions that check if the specific interaction/action (the verb) mentioned in the QUESTION is explicitly tested or observed in PAPER A.
* Repeat the above checks for PAPER B.
* Include questions about any statistical significance, quantitative measurements (e.g., fold change, p-values), or arithmetic required to interpret the results.
Next, answer each of the questions. Make sure to work step by step to verify the claims in the papers.
Finally, use these answers to evaluate the criteria. Output the ### EXPLANATION (Text). Then, use the EXPLANATION to output the ### EVALUATION (JSON).
EXAMPLE:
### QUESTION
Does treatment with Compound X inhibit the expression of the MYC gene?
### PAPER A
We performed a screening of 50 compounds to identify potential inhibitors of cell growth. Compound X was included in the screen. We observed that cells treated with Compound X showed a 40% reduction in proliferation. The discussion section hypothesizes that this might be due to interference with the MYC pathway, but no direct measurement of MYC gene expression levels (mRNA or protein) was performed.
### PAPER B
To determine the mechanism of action, we treated HeLa cells with 10 µM Compound X for 24 hours. qPCR analysis revealed that MYC mRNA levels decreased by 3.5-fold compared to control (p < 0.01). Western blot analysis confirmed a corresponding decrease in MYC protein levels.
### EXPLANATION
To answer the question "Does Compound X inhibit MYC expression?", we need direct evidence of a change in MYC levels.
1. Does Paper A answer it? Paper A measures cell proliferation (growth), not MYC expression. It only hypothesizes a link to the MYC pathway. It lacks direct evidence of the interaction.
2. Does Paper B answer it? Yes. Paper B explicitly performs qPCR and Western blots targeting MYC.
3. Quantitative Check: Paper B reports a 3.5-fold decrease with statistical significance (p < 0.01), which confirms inhibition.
4. Comparison: Paper B provides direct, quantitative evidence of the specific interaction asked in the question. Paper A only infers it loosely.
Therefore, Paper B is the better source.
### JSON
{"Better Paper": "Paper B"}
Remember the instructions:
You are an expert LLM evaluator.
First, output a list of step-by-step questions.
Next, answer each of the questions.
Finally, Output the ### EXPLANATION (Text) and ### EVALUATION (JSON) where "Better Paper" must be either "Paper A" or "Paper B".
### QUESTION
<question>
Does BCL2L1 activate BAD?
### PAPER A
Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death
Abstract
To extend the mammalian cell death pathway, we screened for further Bcl-2 interacting proteins. Both yeast two-hybrid screening and lambda expression cloning identified a novel interacting protein, Bad, whose homology to Bcl-2 is limited to the BH1 and BH2 domains. Bad selectively dimerized with Bcl-xL as well as Bcl-2, but not with Bax, Bcl-xs, Mcl-1, A1, or itself. Bad binds more strongly to Bcl-xL than Bcl-2 in mammalian cells, and it reversed the death repressor activity of Bcl-xL, but not that of Bcl-2. When Bad dimerized with Bcl-xL, Bax was displaced and apoptosis was restored. When approximately half of Bax was heterodimerized, death was inhibited. The susceptibility of a cell to a death signal is determined by these competing dimerizations in which levels of Bad influence the effectiveness of Bcl-2 versus Bcl-xL in repressing death.
### PAPER B
Boo, a novel negative regulator of cell death, interacts with Apaf-1
Abstract
In this report, we describe the cloning and characterization of Boo, a novel anti-apoptotic member of the Bcl-2 family. The expression of Boo was highly restricted to the ovary and epididymis implicating it in the control of ovarian atresia and sperm maturation. Boo contains the conserved BH1 and BH2 domains, but lacks the BH3 motif. Like Bcl-2, Boo possesses a hydrophobic C-terminus and localizes to intracellular membranes. Boo also has an N-terminal region with strong homology to the BH4 domain found to be important for the function of some anti-apoptotic Bcl-2 homologues. Chromosomal localization analysis assigned Boo to murine chromosome 9 at band d9. Boo inhibits apoptosis, homodimerizes or heterodimerizes with some death-promoting and -suppressing Bcl-2 family members. More importantly, Boo interacts with Apaf-1 and forms a multimeric protein complex with Apaf-1 and caspase-9. Bak and Bik, two pro-apoptotic homologues disrupt the association of Boo and Apaf-1. Furthermore, Boo binds to three distinct regions of Apaf-1. These results demonstrate the evolutionarily conserved nature of the mechanisms of apoptosis. Like Ced-9, the mammalian homologues Boo and Bcl-xL interact with the human counterpart of Ced-4, Apaf-1, and thereby regulate apoptosis.